OCT4 gene (official symbol POU5F1) is a mammalian POU transcription factor that affects the maintenance of self-renewal and pluripotency, which are the central features of embryonic stem cells.
metastasis, 3, 4 and OCT4 could suppress the metastatic potential of breast cancer cells (BCCs). 5 OCT4 has been used as a marker of cancer stem cells and has distinct functions in different pathways in cancer cells. Some studies have revealed that aberrant expression of OCT4 is linked to a variety of human cancers. [6] [7] [8] Furthermore,
epigenetic mechanisms, such as DNA modification, is involved in tumour-propagating phenotype induced by OCT4. 9 However, the role and underlying mechanism of OCT4 in BC progression remain elusive.
Human cancers have been found to be associated with aberrant DNA hypermethylation at CpG islands of tumour suppressor genes, most of which are unmethylated in normal cells. 10 DNMT1
is a major DNA methyltransferase that is responsible for maintaining the methylation status during DNA replication. 11 DNMT3a and DNMT3b mainly perform de novo methylation of either unmethylated DNA or hemimethylated DNA to assist in maintenance. 12 Previous studies demonstrated that the stem cell pluripotent markers OCT4 and Nanog could regulate DNA methylation during differentiation in embryonic stem cells, and changes in DNA methylation patterns result in altered cell proliferation. 13 Additionally, DNA methylation is associated with tumour proliferation and metastasis through the extracellular signal-regulated kinase (ERK) signalling pathway. 14,15 ERK1/2, also known as p42/44 mitogenactivated protein kinase (MAPK), can be activated by a variety of growth factors and has many substrates. ERK signalling promotes the activated GTP-bound Ras proteins to activate the Raf-MEK-ERK kinase cascade by a series of phosphorylation events of the kinases. 16 The Ras-ERK pathway mediates various cellular processes, including cell growth, proliferation, differentiation, survival and migration. 17, 18 Our recent study using the next-generation sequencing (NGS) showed that overexpression of OCT4 in human hair follicle mesenchymal stem cells up-regulated the expression of 1181 genes, including KRAS gene, which is the upstream of ERK signalling pathway. 19 Therefore, the correlation of the stem cell pluripotent marker OCT4, DNA methylation and ERK signalling pathway in breast cancer proliferation should be examined. However, the present studies demonstrate that OCT4 exerts dual effects in breast cancer, 5, 20 which may be related to the multiple intrinsic genes involved in different breast cancer subtypes, especially estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2). Estrogen receptor alpha-positive (ERα+) subtype accounts for approximately 80% of all breast cancers, which is the most common cancer in women. 21 Up to 50% of ERα+ primary BC lose ERα expression in recurrent tumours, conferring resistance to tamoxifen therapy. 22 Inactivation of ESR1 gene via methylation strongly correlates with poor prognosis as well as an aggressive phenotype in TNBC. 22 Additionally, ERα can be complexed with OCT4 to promote tamoxifen resistance in breast cancer cells. 23 In the current study, we provide evidence that OCT4 is down-regulated in invasive breast cancer, which plays a key role in BCC prolifer- 
| Western blot analysis
Western blot analysis was conducted according to our previous protocol. 24 The following antibodies were used: OCT4 (1:1000;
Abcam, ab19857), β-actin (1:2000; CST, #3700), DNMT1 (1:1000;
Abcam, ab13537), Ras (1:1000; Abcam, ab52939), Raf1 (1:1000;
Abcam, ab137435), P-ERK (1:1000; CST, #4377s), ERK (1:1000; CST, #4695s), ER alpha (1:1000; CST, #8644s) and ISL-1 (1:100; Abcam, ab178400).
| Reverse transcription PCR
Total RNA was collected using TRIzol reagent (Invitrogen). Reverse transcription PCR (RT-PCR) was conducted according to our previous protocol. 24 GAPDH was used as an endogenous control. The PCR primers are shown in Table 1 and Table S1 . The reaction products were resolved on 1.5% agarose gels and visualized by staining with ethidium bromide. The image was observed and photographed under a viltalight lamp using a Gel Imaging System (Bio-Rad Laboratories, Inc, Hercules, CA). The results were analysed by Quantity One 4.4.1 software (Bio-Rad Laboratories, Inc).
| Lentivirus production and lentivirus transduction
The lentivirus vector pLV-EF1α-OCT4-IRES-EGFP and packaging plasmids expressing gag-pol, pVSVG and rev genes were obtained from the 
| Cell proliferation assay

| Plate colony formation assay
In 6-well plate, cells were seeded into each well with 2 mL DMEM supplemented with 10% FBS. After 2 weeks, the resulting colonies were fixed with methanol at room temperature for 15 minute and then stained with Giemsa for 20 minute. Colonies were counted.
The colony formation index was defined as the ratio of colony numbers to the initial numbers of the cells plated in each well (100 cells/well).
| Soft agar colony formation assay
Cell suspensions were mixed with 1.2% soft agar in DMEM containing 20% FBS. In 6-well plate, cells were seeded into each well with 2 mL DMEM supplemented with 10% FBS. Next day, the cell suspension was removed. After 2 weeks, the colonies were counted. The colony formation index was defined as the ratio of colony numbers to the initial numbers of the cells plated in each well (100 cells/well).
| Immunofluorescence
Cells were seeded on small coverslips. After washing three times with PBS, the cells were fixed with 4% paraformaldehyde for 10 minute at room temperature. The cells were incubated with 0.1% Triton X-100
and BSA for 1 hour and then incubated with Ki67 antibody (1:200;
Abcam, ab15580) at 4°C overnight. After washing three times with PBS, the cells were incubated with secondary antibody (1:1000; CST, #8889) for 1 hour. After washing three times with PBS, cells were stained with DAPI for nuclei (D8417; Sigma). Tumour volumes were determined according to the following formula:
| Animal model
(length × width 2 )/2. After the last measurement of tumour volume, the mice were sacrificed under anaesthesia with 5 mg/100 g body weight sodium pentobarbital, and tumour tissues were removed.
| Reagents
Cells were treated with various concentrations and durations of the DNA methyltransferase inhibitor zebularine (Sigma, Z4775) and 5-aza-dC (Sigma, A3656) and the estrogen receptor (ERα) antagonist AZD9496 (MCE, HY-12870).
| Co-Immunoprecipitation
Cells were lysed in IP Lysis/Wash Buffer supplemented with phenylmethane sulfonyl fluoride (PMSF) and protease inhibitor cocktail (PIC) at 4°C for 30 minute and then centrifuged at 13 000 g for 20 minute at 4°C. Lysate was immunoprecipitated with the
TA B L E 1 PCR primers sequences
Gene name Sequence 5′→3′
RT-PCR primers
OCT4
Sense CTGAAGCAGAAGAGGATCAC Antisense GACCACATCCTTCTCGAGCC
ISL1
Sense GCGGAGTGTAATCAGTATTTGGA Antisense GCATTTGATCCCGTACAACCT
ESR1
Sense TGATGAAAGGTGGGATACGAAA Antisense GGCTGTTCTTCTTAGAGCGTTTG 
GAPDH
| Immunohistochemistry
All samples were fixed in 4% paraformaldehyde overnight at 
| Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using the EZ Magna ChIP G chromatin immunoprecipitation kit (Millipore 
| Statistical analysis
Differences between means of independent groups were tested using unpaired Student's t -test. Analyses were carried out using GraphPad Prism 7 (GraphPad software). P values < 0.05 were considered statistically significant. Each experiment was repeated three times.
| RE SULTS
| OCT4 expression is down-regulated in breast cancer tissues
Previous analyses of OCT4 expression in human somatic tumour cell lines showed that OCT4 expression was absent in MCF-7 and HeLa cells compared with nTera cells. 25 In the Finak Breast data set, we found that the POU5F1 mRNA level was significantly decreased in invasive breast cancer compared to the breast samples with all four probes ( Figure 1A ). Consistently, OCT4 expression declined in 40 human breast cancer tissues relative to 10 normal breast tissues, as
shown by using Western blot and IHC analyses ( Figure 1B,C) . These results indicate that OCT4 might play an important role in suppressing breast cancer progression.
| OCT4 plays an important role in breast cancer proliferation in vitro and in vivo
To assess the role of OCT4 in BCCs, we established stable OCT4- All of the above genes were not expressed in MDA-MB-231 cells.
OCT4A, OCT4B, OCT4-pg1, OCT4-pg4, OCT4-pg5 and OCT4-pg6
were expressed at low levels in MCF-7 cells, and OCT4-pg2, OCT4-pg3 and OCT4-pg7 were not expressed in MCF-7 cells ( Figure S2A ). formation of MDA-MB-231 cells ( Figure 3A,B) . However, the tumour volume of the OCT4-induced MCF-7 group was decreased compared with the control group, and the positive expression for Ki67 was decreased in OCT4-induced MCF-7 cells (Figure 3C,D) .
Collectively, these findings demonstrate that OCT4 plays opposite roles in the tumour-propagating capacity of TNBC and luminal subtype cells in vitro and in vivo. 
| 5-aza-dC and zebularine inhibit MDA-MB-231-OCT4 cell proliferation via inactivation of ERK signalling pathway
To investigate whether OCT4 affects cell proliferation by regulating DNMT1 and ERK signalling pathway, we treated 
| ISL1 expression is associated with overall survival in breast cancer
We analysed DNMT1 downstream target ISL1, which is considered as a tumour suppressor gene and is hypermethylated in cancer. The log-rank test P-value is shown ISL1 expression was correlated to tumour size, molecular subtype, ER, PR, HER2 and Ki67 status (Table 2) . Moreover, we constructed Kaplan-Meier curves for the overall survival (OS), which indicated that patients with ISL1-positive tumours had a higher OS rate ( Figure 6E ). These results demonstrate that ISL1 is a tumour suppressor gene in BC and may be associated with tumorigenesis and progression in BC.
| OCT4 interacting with ERα suppresses cell proliferation of MCF-7 cells
To elucidate the mechanism of the dual functions of OCT4 in proliferation of different subtypes of BCC, we hypothesized that the opposing roles of OCT4 in cell proliferation might be associated with the intrinsic characteristics of BCCs. Previous studies showed that DNMT1 was negatively correlated with ERα in breast cancer. 31 Therefore, we tested ERα expression in MDA-MB-231-OCT4
and MCF-7-OCT4 cells by using PCR and Western blot analyses. 
| D ISCUSS I ON
A review of the published literature reveals that OCT4 is absent in somatic tumour cell lines, indicating its tumour-suppressive effects.
However, the link between OCT4 and tumour progression has been poorly investigated. In this study, our analysis of human breast cancer data reveals that OCT4 is down-regulated in breast cancer relative The transcription factor OCT4 is a stem cell marker that functions in the maintenance of self-renewal and pluripotency. OCT4
regulates target genes to play the opposite roles of OCT4 in tumorigenesis and cancer progression, which is a complicated process.
Recent studies show that OCT4 may correlate with cancer progression. However, the majority of adult somatic tumour cells are differentiated without the capacity for self-renewal. OCT4 expression is lost upon additional differentiation and maturation, 35 associated with DNA methylation of OCT4. 36 Additionally, in human in the female rat hypothalamus. 49 However, the relationship between ERα and ISL1 requires further investigation.
In summary, this study demonstrates that OCT4 is involved in tumour-proliferative capacity by modulating DNMT1/ISL1 expression and ERK signalling pathway. We propose that OCT4 suppresses BCC proliferation in an ERα-dependent manner. Our current work 
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